Education
About Us
Working with TipRanks
Follow Us
Corcept Therapeutics Inc. (CORT)
NASDAQ:CORT
CORT Stock Chart & Stats
$37.04
$0.08(0.16%)
At close: 4:00 PM EST
$37.04
$0.08(0.16%)
Day’s Range― - ―
52-Week Range$32.99 - $117.33
Previous CloseN/A
Volume78.39K
Average Volume (3M)2.19M
Market Cap
$3.90B
Enterprise Value$9.51B
Total Cash (Recent Filing)$421.68M
Total Debt (Recent Filing)$6.36M
Price to Earnings (P/E)40.4
Beta0.51
Next Earnings
Feb 18, 2026EPS Estimate
0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.16
Shares Outstanding105,188,220
10 Day Avg. Volume2,491,852
30 Day Avg. Volume2,189,175
Financial Highlights & Ratios
PEG Ratio1.15
Price to Book (P/B)7.65
Price to Sales (P/S)7.71
P/FCF Ratio26.55
Enterprise Value/Market Cap2.44
Enterprise Value/Revenue12.83
Enterprise Value/Gross Profit13.07
Enterprise Value/Ebitda131.25
Forecast
1Y Price Target
$101.25Price Target Upside173.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)0.57
Revenue Forecast (FY)$979.39M
Bulls Say, Bears Say
Bulls Say
Drug ApprovalThe NDA is under FDA review with a PDUFA date of 7-11-2026, and there is an 80% probability of success for an FDA approval.
Financial StabilityCorcept reported cash and cash equivalents of $421.0M, which is believed to be sufficient to fund operations for the foreseeable future.
Market ExclusivityRelacorilant benefits from multiple patents and orphan drug designation, offering market exclusivity in the US and EU, which could protect against generic threats.
Bears Say
Distribution ChallengesThe departure of Optime Care, the exclusive distributor for Korlym, has delayed Corcept's strategy to have at least two pharmacies operational, affecting near-term sales projections.
Generic CompetitionKorlym's generic pressure from Teva could kick in next year; we also see unfavorable regulatory outcomes for ongoing litigation cases, adding additional pressure.
Regulatory ChallengesThe FDA issued a Complete Response Letter requiring additional confirmatory evidence for relacorilant, which suggests a potential delay in its approval process.
Corcept Therapeutics News
CORT FAQ
What was Corcept Therapeutics Inc.’s price range in the past 12 months?
Corcept Therapeutics Inc. lowest stock price was $32.99 and its highest was $117.33 in the past 12 months.
What is Corcept Therapeutics Inc.’s market cap?
Corcept Therapeutics Inc.’s market cap is $3.90B.
When is Corcept Therapeutics Inc.’s upcoming earnings report date?
Corcept Therapeutics Inc.’s upcoming earnings report date is Feb 18, 2026 which is in 33 days.
How were Corcept Therapeutics Inc.’s earnings last quarter?
Corcept Therapeutics Inc. released its earnings results on Nov 04, 2025. The company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.164 by -$0.004.
Is Corcept Therapeutics Inc. overvalued?
According to Wall Street analysts Corcept Therapeutics Inc.’s price is currently Undervalued.
Does Corcept Therapeutics Inc. pay dividends?
Corcept Therapeutics Inc. does not currently pay dividends.
What is Corcept Therapeutics Inc.’s EPS estimate?
Corcept Therapeutics Inc.’s EPS estimate is 0.26.
How many shares outstanding does Corcept Therapeutics Inc. have?
Corcept Therapeutics Inc. has 105,188,220 shares outstanding.
What happened to Corcept Therapeutics Inc.’s price movement after its last earnings report?
Corcept Therapeutics Inc. reported an EPS of $0.16 in its last earnings report, missing expectations of $0.164. Following the earnings report the stock price went up 7.806%.
Which hedge fund is a major shareholder of Corcept Therapeutics Inc.?
Currently, no hedge funds are holding shares in CORT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corcept Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$101.25 (173.35% Upside)
$101.25 (173.35% Upside)
Blogger Sentiment
Bullish
CORT Sentiment 87%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 343.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $364.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.19%
12-Months-Change
Fundamentals
Return on Equity
16.47%
Trailing 12-Months
Asset Growth
5.02%
Trailing 12-Months
Company Description
Corcept Therapeutics Inc.
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
CORT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth and a robust pipeline, particularly in hypercortisolism and oncology. However, challenges such as a significant decline in net income and unresolved patent litigation present concerns.View all CORT earnings summariesCORT Stock 12 Month Forecast
Average Price Target
$101.25
▲(173.35% Upside)
Technical Analysis
Jazz Pharmaceuticals
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
Legend Biotech
―
Ownership Overview
11.68% Insiders
17.20% Mutual Funds
0.03% Other Institutional Investors
50.65% Public Companies and Individual Investors